Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
Clin. transl. oncol. (Print)
; 14(3): 163-168, mar. 2012. tab, ilus
Artigo
em Inglês
| IBECS
| ID: ibc-126171
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Anthracyclines are frequently used in the adjuvant setting for breast cancer treatment since it is considered that anthracycline-based chemotherapy treatment benefits breast cancer patients. Nonetheless, these drugs are associated with severe side effects and predictive factors, for sensitivity to anthracyclines, are warranted in clinical practice. Topoisomerase 2 alpha (TOP2A) is considered to be the molecular target of these drugs. The potential predictive value of TOP2A amplification and overexpression has been extensively studied in breast cancer patients treated with anthracyclines. However, results are not conclusive. In this paper, we review some of the published studies addressing the predictive value of TOP2A as well as the cellular functions of this enzyme and its status in breast cancer tissue (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias da Mama
/
Biomarcadores Tumorais
/
DNA Topoisomerases Tipo II
/
Antraciclinas
/
Modelos Biológicos
/
Antígenos de Neoplasias
Tipo de estudo:
Estudo diagnóstico
/
Estudo de avaliação
/
Estudo prognóstico
/
Fatores de risco
Limite:
Animais
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2012
Tipo de documento:
Artigo
Instituição/País de afiliação:
Hospital Clínico San Carlos/Spain
/
Hospital General Universitario Gregorio Marañón/Spain